NFL Biosciences SA

As of December 31, 2024, NFL Biosciences SA carries a market capitalization of 19.37M, placing it among publicly traded companies globally. Its enterprise value stands at 17.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

NFL Biosciences SA's next confirmed earnings release is scheduled for October 28, 2026.

As of December 31, 2024, NFL Biosciences SA has 9.83M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, NFL Biosciences SA maintains a current ratio of 1.29, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 23, 2026, NFL Biosciences SA's stock has declined approximately 51.27% over the past 52 weeks. The 50-day moving average sits at 0.76, while the 200-day moving average is 0.96.

As of December 31, 2024, NFL Biosciences SA holds 2.11M in cash and equivalents against 81,950.00 in total debt, resulting in a net debt position of -1.83M. Total book value stands at 976,430.00, with working capital of 747,220.00 providing operational flexibility.